TSE:THTheratechnologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Theratechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$2.36 -0.15 (-5.98 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's RangeC$2.29Now: C$2.36▼C$2.5750-Day RangeC$2.05MA: C$3.03▼C$4.2952-Week RangeC$1.93Now: C$2.36▼C$8.89Volume44,700 shsAverage Volume123,015 shsMarket CapitalizationC$181.61 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingTheratechnologies has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$8.44, Theratechnologies has a potential upside of 257.5% from its current price of C$2.36.Amount of Analyst CoverageTheratechnologies has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesTheratechnologies has received 266 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTheratechnologies has received 294 “underperform” votes. (Add your “underperform” vote.)Community SentimentTheratechnologies has received 52.50% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Theratechnologies and other stocks. Vote “Outperform” if you believe TH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTheratechnologies does not currently pay a dividend.Dividend GrowthTheratechnologies does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theratechnologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$15,450.00 in company stock and sold C$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Theratechnologies are expected to decrease by -100.00% in the coming year, from C$0.13 to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theratechnologies is -14.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theratechnologies is -14.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioTheratechnologies has a PEG Ratio of 219.73. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTheratechnologies has a P/B Ratio of 7.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.72 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:TH Previous Symbol CUSIPN/A CIKN/A Webhttp://www.theratech.com/ Phone+1-514-3367800Debt Debt-to-Equity Ratio204.32 Current Ratio2.05 Quick Ratio1.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio18.15 P/E Growth219.73 Sales & Book Value Annual SalesC$63.22 million Price / Sales2.87 Cash FlowC$0.52 per share Price / Cash Flow4.51 Book ValueC$0.32 per share Price / Book7.31Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees32 Outstanding Shares76,953,000Market CapC$181.61 million Next Earnings Date4/14/2020 (Estimated) OptionableNot Optionable Receive TH News and Ratings via Email Sign-up to receive the latest news and ratings for TH and its competitors with MarketBeat's FREE daily newsletter. TSX:TH Rates by TradingView Theratechnologies (TSE:TH) Frequently Asked Questions How has Theratechnologies' stock been impacted by COVID-19 (Coronavirus)? Theratechnologies' stock was trading at C$3.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TH shares have decreased by 21.3% and is now trading at C$2.36. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Theratechnologies? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Theratechnologies. When is Theratechnologies' next earnings date? Theratechnologies is scheduled to release its next quarterly earnings announcement on Tuesday, April 14th 2020. View our earnings forecast for Theratechnologies. How were Theratechnologies' earnings last quarter? Theratechnologies Inc (TSE:TH) posted its quarterly earnings data on Tuesday, February, 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.03. The company had revenue of $21.80 million for the quarter, compared to analysts' expectations of $21.75 million. View Theratechnologies' earnings history. What price target have analysts set for TH? 5 equities research analysts have issued 12-month price objectives for Theratechnologies' shares. Their forecasts range from C$5.75 to C$15.00. On average, they anticipate Theratechnologies' stock price to reach C$8.44 in the next twelve months. This suggests a possible upside of 257.5% from the stock's current price. View analysts' price targets for Theratechnologies. Has Theratechnologies been receiving favorable news coverage? News stories about TH stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Theratechnologies earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutTheratechnologies. Who are some of Theratechnologies' key competitors? Some companies that are related to Theratechnologies include Mesoblast (MSB), Bellus Health (BLU), Oxford BioMedica (OXB), Trillium Therapeutics (TRIL), Biotest (BIO), CEL-SCI (CVM), Cel-Sci (CVM), Silence Therapeutics (SLN), Paradigm Biopharmaceuticals (PAR), ProMetic Life Sciences (PLI), Starpharma (SPL), Pfenex (PFNX), Pfenex (PFNX), TELIX Pharmaceutical (TLX) and Emblem (EMC). What other stocks do shareholders of Theratechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI), BCE (BCE), Theratechnologies (THERF), ProMetic Life Sciences (PLI), Teranga Gold (TGZ), United Therapeutics (UTHR), Endeavour Mining (EDV), Nemaska Lithium (NMX), Shopify (SHOP) and Catalyst Pharmaceuticals (CPRX). Who are Theratechnologies' key executives? Theratechnologies' management team includes the following people: Mr. Luc Tanguay, Pres, CEO & Non-Independent Director (Age 61)Mr. Philippe Dubuc MBA, Sr. VP & CFO (Age 52)Mr. Jocelyn Lafond, VP of Legal Affairs & Corp. Sec. (Age 51)Mr. Denis Boucher B.A., L.L.B., VP of Communications & Corp. Affairs (Age 53)Mr. Christian Marsolais, Sr. VP & Chief Medical Officer (Age 56) What is Theratechnologies' stock symbol? Theratechnologies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TH." How do I buy shares of Theratechnologies? Shares of TH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Theratechnologies' stock price today? One share of TH stock can currently be purchased for approximately C$2.36. How big of a company is Theratechnologies? Theratechnologies has a market capitalization of C$181.61 million and generates C$63.22 million in revenue each year. Theratechnologies employs 32 workers across the globe. View additional information about Theratechnologies. What is Theratechnologies' official website? The official website for Theratechnologies is http://www.theratech.com/. How can I contact Theratechnologies? Theratechnologies' mailing address is 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada. The company can be reached via phone at +1-514-3367800. This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: What is the role of the G-20?
